|
GATC expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.90809999917252E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.00740000000366E-06 |
| Normal-vs-Stage2 |
7.217500E-04 |
| Normal-vs-Stage3 |
1.68239999709385E-08 |
| Normal-vs-Stage4 |
2.47899999972212E-07 |
| Stage1-vs-Stage2 |
8.745000E-01 |
| Stage1-vs-Stage3 |
1.057430E-01 |
| Stage1-vs-Stage4 |
1.453240E-01 |
| Stage2-vs-Stage3 |
2.090000E-01 |
| Stage2-vs-Stage4 |
2.626400E-01 |
| Stage3-vs-Stage4 |
9.991200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.88019999861567E-08 |
| Normal-vs-AfricanAmerican |
4.121300E-03 |
| Normal-vs-Asian |
1.56344999999725E-05 |
| Caucasian-vs-AfricanAmerican |
4.392800E-01 |
| Caucasian-vs-Asian |
7.319400E-01 |
| AfricanAmerican-vs-Asian |
3.236600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.64159999985303E-07 |
| Normal-vs-Female |
1.29849999974674E-07 |
| Male-vs-Female |
3.463800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.94349999999411E-05 |
| Normal-vs-Age(41-60Yrs) |
1.45699999953841E-07 |
| Normal-vs-Age(61-80Yrs) |
8.50869996682491E-09 |
| Normal-vs-Age(81-100Yrs) |
1.041050E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.835900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.313700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.935240E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.735000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.670600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.718600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.360400E-02 |
| Classical-VS-Follicular |
9.857200E-01 |
| Classical-VS-Other |
1.196360E-01 |
| Classical-VS-Normal |
4.03689999983747E-07 |
| Tall-VS-Follicular |
1.415390E-01 |
| Tall-VS-Other |
3.253800E-01 |
| Tall-VS-Normal |
1.06730000004607E-06 |
| Follicular-VS-Other |
1.947650E-01 |
| Follicular-VS-Normal |
1.444560E-04 |
| Other-VS-Normal |
6.038800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.4302000002403E-07 |
| Normal-vs-N1 |
2.78020000354928E-08 |
| N0-vs-N1 |
1.060570E-01 |
|
|
